FindTrial
Sign In

Placebo Linezolid

DRUG2 trials

Sponsors

Bayer, Global Alliance for TB Drug Development

Conditions

Bacterial InfectionsExtensively Drug-Resistant TuberculosisPre-XDR-TBTuberculosisTuberculosis, MDRTuberculosis, Multidrug-ResistantTuberculosis, PulmonaryXDR-TB

Phase 3

Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
CompletedNCT02066402
BayerBacterial Infections
Start: 2014-03-04End: 2016-04-18Updated: 2017-06-07
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
CompletedNCT03086486
Global Alliance for TB Drug DevelopmentExtensively Drug-Resistant Tuberculosis, Pre-XDR-TB, Tuberculosis +4
Start: 2017-11-21End: 2022-02-08Updated: 2023-06-29

Related Papers

Dose optimization of TBI-223 for enhanced therapeutic benefit compared to linezolid in antituberculosis regimen
Nature Communications2024-08-2512 citations
Analysis of Dynamic Efficacy Endpoints of the Nix-TB Trial
Clinical Infectious Diseases2023-02-2115 citations
Bedaquiline–Pretomanid–Linezolid Regimens for Drug-Resistant Tuberculosis
New England Journal of Medicine2022-08-31497 citations
Safety of Treatment Regimens Containing Bedaquiline and Delamanid in the endTB Cohort
Clinical Infectious Diseases2022-01-1250 citations
Evaluating newly approved drugs for multidrug-resistant tuberculosis (endTB): study protocol for an adaptive, multi-country randomized controlled trial.
2021-09-2522 citations
Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis
Clinical Infectious Diseases2021-08-1357 citations
Efficacy and Safety of Tedizolid Phosphate versus Linezolid in a Randomized Phase 3 Trial in Patients with Acute Bacterial Skin and Skin Structure Infection.
2019-06-2420 citations